NNLX NanoLogix Inc (CE)

NanoLogix, Inc. (PINKSHEETS: NNLX) announces that the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU. These applications were filed in order to obtain intellectual property protection for the company's technology in countries viewed as representing the largest potential international market for BNP rapid detection, a revolutionary sandwiched-membrane Petri-based technology that can reduce microorganism detection times by 100-400%.

At the company's September 25th shareholder meeting, the support for all proposals presented by the company for shareholder approval was overwhelmingly positive, with all shareholder-rights/takeover-defense plan proposals receiving 98-99% of the 64 million shares voted out of roughly 101 million shares outstanding.

The company has reclaimed full rights to 18 patents previously licensed to Nutra Pharma Corporation after failure of Nutra Pharma to pay the balance of patent royalties due for 2008 and the first half of 2009. Nutra Pharma was served notice of their default in July. NanoLogix has returned the 18 patents to the company portfolio and will pursue development and marketing of select technological aspects of the patents.

NanoLogix's April press release: "New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague," was highlighted in the latest issue of the Department of Defense Quarterly, "CBRNIAC," from the Chemical, Biological, Radiological and Nuclear Defense Information Analysis Center. The publication can be accessed at: https://www.cbrniac.apgea.army.mil/Products/Newsletter/Pages/default.aspx

NanoLogix has received notification from New Brunswick Scientific of a November 20th shipping date for ordered production equipment for its cleanroom production facility at the company's Hubbard, Ohio headquarters. This order consists of four machines for production of BNP rapid-detection kits and is anticipated to be the first of many for kit production.

NanoLogix management, staff, and directors would like to congratulate Corporate Counsel David R. Barnhizer for his recent three-year appointment as Visiting Professor to the University of Westminster, London. Professor Barnhizer will continue as corporate counsel.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases. In addition to medical, National Defense, and Homeland Security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents pending or granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.

More information on NanoLogix is available at: www.nanologix.com

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact: NanoLogix, Inc. Investor Relations Carol Surrena Telephone: 330-534-0800 E-mail: Email Contact